One of the ten or so shareholders who were communicating last fall had done a good job of gathering research links about anatabine and sending them to pharma companies. Later, "we" added a letter written by a German doctor who strongly endorsed anatabine. Is it worth sending info to the company you mentioned?
It will soon be a year that I corresponded with Mullan at Roskamp, he agreed to me with us by phone, and then revoked the offer. When I emailed him and said I considered his move hostile to RCPIQ shareholders, he called me. Near the end of the conversation, he asked me to let him know if we had any results trying to contact George Miller. I think he said that because, wherever he went, he wanted rights to anatabine. Now he is with Archer. I don't see any reason why he would not just jump right over the dead body that is rock creek, ignore shareholders, and look to bid on the IP for himself and Archer. Let's hope he does not get the IP by default, because no one else bids on it.
